Rock Springs Capital Management LP — 13F Holdings & Portfolio
CIK 1595725 · latest 13F-HR filed 2026-08-14
Rock Springs Capital Management LP manages $2.05B in 13F-reported U.S. long-equity assets across 104 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RVMD (10.10%), TVTX (6.04%), LLY (5.78%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 17 new positions and exited 13; 54 existing positions rose in reported value and 24 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 44%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 24, 2026.
SUITE 1070
BALTIMORE, MD 21202
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| BUSSARD, GORDON, MARGRAF ("MARK") Control | MEMBER/LIMITED PARTNER since Mar 2013 | 50–75% | Individual |
| JENNER, KRIS, HARLAN Control | MEMBER/LIMITED PARTNER since Mar 2013 | 50–75% | Individual |
| ROCK SPRINGS CAPITAL LLC Control | GENERAL PARTNER since Mar 2013 | Less than 5% | Domestic Entity |
| ETOH, NNAMDI, C | CHIEF FINANCIAL OFFICER since Jan 2021 | Less than 5% | Individual |
| O'CONNOR, AIDAN, HUGH | CHIEF COMPLIANCE OFFICER AND GENERAL COUNSEL since Oct 2022 | Less than 5% | Individual |
| BUSSARD, GORDON, MARGRAF ("MARK") Control Indirect owner via ROCK SPRINGS CAPITAL LLC | MEMBER since Mar 2013 | 50–75% | Individual |
| JENNER, KRIS, HARLAN Control Indirect owner via ROCK SPRINGS CAPITAL LLC | MEMBER since Mar 2013 | 50–75% | Individual |
Ownership & leadership changes · 11 filings with changes since Aug 23, 2013
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedMCPHAIL, GRAHAM, MORGAN · MEMBER/LIMITED PARTNER · 25–50% · control person · listed since Mar 2013
- No longer listedMCPHAIL, GRAHAM, MORGAN · MEMBER · 25–50% · indirect via ROCK SPRINGS CAPITAL LLC · control person · listed since Mar 2013
- ChangedBUSSARD, GORDON, MARGRAF ("MARK") · ownership 25–50% → 50–75%
- ChangedBUSSARD, GORDON, MARGRAF ("MARK") · indirect via ROCK SPRINGS CAPITAL LLC: ownership 25–50% → 50–75%
- ChangedJENNER, KRIS, HARLAN · ownership 25–50% → 50–75%
- ChangedJENNER, KRIS, HARLAN · indirect via ROCK SPRINGS CAPITAL LLC: ownership 25–50% → 50–75%
- No longer listedSEIDMAN, JILL, REYNOLDS · CHIEF COMPLIANCE OFFICER AND GENERAL COUNSEL · Less than 5% · listed since Jul 2016
- AddedO'CONNOR, AIDAN, HUGH · CHIEF COMPLIANCE OFFICER AND GENERAL COUNSEL · Less than 5%
- No longer listedLABEL, HALLIE, DINKELSPIEL · CHIEF OPERATING OFFICER · Less than 5% · listed since Sep 2014
- ChangedETOH, NNAMDI, C · title CONTROLLER → CHIEF FINANCIAL OFFICER
- ChangedBUSSARD, GORDON, MARGRAF ("MARK") · title MANAGING MEMBER/LIMITED PARTNER → MEMBER/LIMITED PARTNER
- ChangedBUSSARD, GORDON, MARGRAF ("MARK") · indirect via ROCK SPRINGS CAPITAL LLC: title MANAGING MEMBER → MEMBER
- ChangedJENNER, KRIS, HARLAN · title MANAGING MEMBER/LIMITED PARTNER → MEMBER/LIMITED PARTNER
- ChangedJENNER, KRIS, HARLAN · indirect via ROCK SPRINGS CAPITAL LLC: title MANAGING MEMBER → MEMBER
- ChangedMCPHAIL, GRAHAM, MORGAN · title MANAGING MEMBER/LIMITED PARTNER → MEMBER/LIMITED PARTNER
- ChangedMCPHAIL, GRAHAM, MORGAN · indirect via ROCK SPRINGS CAPITAL LLC: title MANAGING MEMBER → MEMBER
- No longer listedBRODY, ERIC, ANDREW · VICE PRESIDENT--FINANCE AND OPERATIONS · Less than 5% · listed since Jul 2016
- AddedETOH, NNAMDI, C · CONTROLLER · Less than 5%
- ChangedBUSSARD, GORDON, MARGRAF ("MARK") · title MANAGING DIRECTOR/LIMITED PARTNER → MANAGING MEMBER/LIMITED PARTNER
- ChangedJENNER, KRIS, HARLAN · title MANAGING DIRECTOR/LIMITED PARTNER → MANAGING MEMBER/LIMITED PARTNER
- ChangedMCPHAIL, GRAHAM, MORGAN · title MANAGING DIRECTOR/LIMITED PARTNER → MANAGING MEMBER/LIMITED PARTNER
- No longer listedAPEADU, EVANS · CHIEF COMPLIANCE OFFICER/CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jun 2014
- AddedBRODY, ERIC, ANDREW · VICE PRESIDENT--FINANCE AND OPERATIONS · Less than 5%
- AddedSEIDMAN, JILL, REYNOLDS · CHIEF COMPLIANCE OFFICER AND GENERAL COUNSEL · Less than 5%
- No longer listedROCK SPRINGS CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person · listed since Mar 2013
- AddedLABEL, HALLIE, DINKELSPIEL · CHIEF OPERATING OFFICER · Less than 5%
- Listed againROCK SPRINGS CAPITAL LLC · GENERAL PARTNER · Less than 5% · control person
- No longer listedROCK SPRINGS CAPITAL LLC · GENERAL PARTNER · Less than 5% · control person · listed since Mar 2013
- AddedROCK SPRINGS CAPITAL GP LLC · GENERAL PARTNER · Less than 5% · control person
- No longer listedANNECCHINO, JEFFREY, ARTHUR · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Mar 2013
- AddedAPEADU, EVANS · CHIEF COMPLIANCE OFFICER/CHIEF FINANCIAL OFFICER · Less than 5% · control person
Older changes (2 more filings)
- AddedJENNER, KRIS, HARLAN · MANAGING MEMBER · 25–50% · indirect via ROCK SPRINGS CAPITAL LLC · control person
- ListedANNECCHINO, JEFFREY, ARTHUR · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedBUSSARD, GORDON, MARGRAF ("MARK") · MANAGING DIRECTOR/LIMITED PARTNER · 25–50% · control person
- ListedBUSSARD, GORDON, MARGRAF ("MARK") · MANAGING MEMBER · 25–50% · indirect via ROCK SPRINGS CAPITAL LLC · control person
- ListedJENNER, KRIS, HARLAN · MANAGING DIRECTOR/LIMITED PARTNER · 25–50% · control person
- ListedMCPHAIL, GRAHAM, MORGAN · MANAGING DIRECTOR/LIMITED PARTNER · 25–50% · control person
- ListedMCPHAIL, GRAHAM, MORGAN · MANAGING MEMBER · 25–50% · indirect via ROCK SPRINGS CAPITAL LLC · control person
- ListedROCK SPRINGS CAPITAL LLC · GENERAL PARTNER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- REVOLUTION MEDICINES INC$89.4M +76.0%
- TRAVERE THERAPEUTICS INC$79.9M +181.9%
- ELI LILLY & CO$27.6M +30.4%
- AGILON HEALTH INC$26.1M +1268.5%
- MIRUM PHARMACEUTICALS INC$18.5M +24.7%
Top Trims
- ARGENX SE-$23.0M -32.0%
- INSMED INC-$12.8M -24.9%
- BOSTON SCIENTIFIC CORP-$9.8M -30.2%
- COMPASS THERAPEUTICS INC-$9.8M -55.9%
- ENLIVEN THERAPEUTICS INC-$8.8M -27.2%
New Positions
- ASCENDIS PHARMA A/S$45.0M
- AVALYN PHARMACEUTICALS INC$21.8M
- HEMAB THERAPEUTICS HLDGS INC$21.1M
- PARABILIS MEDICINES INC$15.8M
- OMEROS CORP$6.8M
Exited Positions
- ASCENDIS PHARMA A/S$44.4M
- ARCELLX INC$19.5M
- CENTESSA PHARMACEUTICALS PLC$14.0M
- SOLENO THERAPEUTICS INC$8.6M
- REGENERON PHARMACEUTICALS$7.8M
Rock Springs Capital Management LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $207.0M | 10.10% | 1,105,210 | SH |
| 2 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $123.8M | 6.04% | 2,179,069 | SH |
| 3 | ELI LILLY & CO | LLY | 532457108 | $118.4M | 5.78% | 98,700 | SH |
| 4 | MADRIGAL PHARMACEUTICALS INC | MDGL | 558868105 | $94.0M | 4.59% | 174,999 | SH |
| 5 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $93.4M | 4.56% | 798,145 | SH |
| 6 | RHYTHM PHARMACEUTICALS INC | RYTM | 76243J105 | $76.9M | 3.75% | 692,598 | SH |
| 7 | KYMERA THERAPEUTICS INC | KYMR | 501575104 | $52.0M | 2.54% | 453,156 | SH |
| 8 | ARGENX SE | ARGX | 04016X101 | $48.9M | 2.39% | 52,750 | SH |
| 9 | ASCENDIS PHARMA A/S | ASND | K08588103 | $45.0M | 2.20% | 168,750 | SH |
| 10 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $41.3M | 2.01% | 683,907 | SH |
| 11 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $39.3M | 1.92% | 715,452 | SH |
| 12 | INSMED INC | INSM | 457669307 | $38.6M | 1.88% | 362,150 | SH |
| 13 | PENUMBRA INC | PEN | 70975L107 | $36.5M | 1.78% | 115,750 | SH |
| 14 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $34.4M | 1.68% | 640,317 | SH |
| 15 | ULTRAGENYX PHARMACEUTICAL IN | RARE | 90400D108 | $32.3M | 1.58% | 967,855 | SH |
| 16 | IRHYTHM HOLDINGS INC | IRTC | 450056106 | $32.1M | 1.57% | 269,650 | SH |
| 17 | INTUITIVE SURGICAL INC | ISRG | 46120E602 | $30.4M | 1.48% | 76,460 | SH |
| 18 | AGILON HEALTH INC | AGL | 00857U206 | $28.1M | 1.37% | 262,600 | SH |
| 19 | UNITEDHEALTH GROUP INC | UNH | 91324P102 | $26.5M | 1.29% | 63,750 | SH |
| 20 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $26.0M | 1.27% | 699,146 | SH |
| 21 | ERASCA INC | ERAS | 29479A108 | $25.7M | 1.25% | 1,402,150 | SH |
| 22 | NEUROCRINE BIOSCIENCES INC | NBIX | 64125C109 | $24.4M | 1.19% | 144,750 | SH |
| 23 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $23.6M | 1.15% | 464,625 | SH |
| 24 | TENET HEALTHCARE CORP | THC | 88033G407 | $23.4M | 1.14% | 125,000 | SH |
| 25 | DEXCOM INC | DXCM | 252131107 | $23.1M | 1.13% | 343,000 | SH |
| 26 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $22.9M | 1.12% | 4,330,532 | SH |
| 27 | MINIMED GROUP INC | MMED | 60365F109 | $22.7M | 1.11% | 1,520,000 | SH |
| 28 | BOSTON SCIENTIFIC CORP | BSX | 101137107 | $22.6M | 1.10% | 528,500 | SH |
| 29 | PHARVARIS N V | PHVS | N69605108 | $22.4M | 1.09% | 648,333 | SH |
| 30 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $21.8M | 1.07% | 662,918 | SH |
| 31 | HEMAB THERAPEUTICS HLDGS INC | COAG | 423494103 | $21.1M | 1.03% | 575,432 | SH |
| 32 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $20.9M | 1.02% | 942,154 | SH |
| 33 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $20.1M | 0.98% | 66,750 | SH |
| 34 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $20.0M | 0.97% | 515,917 | SH |
| 35 | AGIOS PHARMACEUTICALS INC | AGIO | 00847X104 | $19.8M | 0.96% | 532,563 | SH |
| 36 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $19.7M | 0.96% | 582,744 | SH |
| 37 | VERA THERAPEUTICS INC | VERA | 92337R101 | $18.3M | 0.90% | 427,584 | SH |
| 38 | TARSUS PHARMACEUTICALS INC | TARS | 87650L103 | $17.4M | 0.85% | 277,087 | SH |
| 39 | HEARTFLOW INC | HTFL | 42238D107 | $16.8M | 0.82% | 573,500 | SH |
| 40 | MBX BIOSCIENCES INC | MBX | 55287L101 | $16.5M | 0.80% | 298,218 | SH |
| 41 | CYTOKINETICS INC | CYTK | 23282W605 | $16.0M | 0.78% | 187,980 | SH |
| 42 | BICARA THERAPEUTICS INC | BCAX | 055477103 | $15.9M | 0.78% | 535,286 | SH |
| 43 | PARABILIS MEDICINES INC | PBLS | 698955101 | $15.8M | 0.77% | 578,028 | SH |
| 44 | ZAI LAB LTD | ZLAB | 98887Q104 | $15.5M | 0.76% | 814,707 | SH |
| 45 | DANAHER CORP DEL | DHR | 235851102 | $14.5M | 0.71% | 76,300 | SH |
| 46 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $14.3M | 0.70% | 456,551 | SH |
| 47 | EVOLENT HEALTH INC | EVH | 30050B101 | $13.6M | 0.66% | 2,500,000 | SH |
| 48 | PTC THERAPEUTICS INC | PTCT | 69366J200 | $13.2M | 0.65% | 162,298 | SH |
| 49 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $13.1M | 0.64% | 484,951 | SH |
| 50 | ZENAS BIOPHARMA INC | ZBIO | 98937L105 | $12.7M | 0.62% | 502,077 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $2.05B | 104 | 0001172661-26-003527 |
| 2026-03-31 | 2026-05-15 | $1.70B | 100 | 0001172661-26-002225 |
| 2025-12-31 | 2026-02-17 | $1.95B | 99 | 0001172661-26-000917 |
| 2025-09-30 | 2025-11-14 | $1.71B | 93 | 0001172661-25-004882 |
SUITE 1070
BALTIMORE, MD 21202